Computational Pathology @
The Netherlands Cancer Institute


  • Home
  • Our Research
  • Our approach
  • Team Science
  • Publications
  • Resources
  • Technologies
  • Data
  • Join Us

Centre of
Computational Pathology
to Personalise Cancer Treatment


Learn More >

to Get the right treatment for the right person at the right Time



Our Vision - Mission






Our team focuses on the development of “Computational Pathology” approaches that combines clinical, pathology and genomics data with image analysis of the tumor to find the balance between over- and under-treatment of women's ovarian and breast cancer. To get the right treatment for the right person at the right time



Learn more >

OUR SCIENTIFIC CHALLENGES TO ADDRESS



Who will benefit from Immunotherapy?





We aim to dissect cancer-immune interactions by digital Pathology to empower personalised immunotherapy...


Learn more >

Who can get targeted treatment?





Histogenomics; can we read mutational processes from pathology images using deep learning to....


Learn more >

Who can be spared chemotherapy?





The last decade, molecularly based personalised treatment strategies such as the 70-gene signature test ....


Learn more >

OPEN SCIENCE





We believe in Open Science and FAIR data. Like many others our lab strives for more transparency and early sharing of data & knowledge. Towards this goal, we do the following...


Learn more >

We Diagnose


Learn more >

We Innovate


Learn more >

We Educate


Learn more >

We Share


Learn more >

TEAM SCIENCE



We strongly believe in Team Science; a collaborative effort to address a scientific challenge
that leverages the strengths and expertise of professionals trained in different fields.


Meet our people >

Hugo Horlings



Iris Nederlof



Jonas Teuwen



Siamak Haijzadeh



Michiel de Maaker



Jan Hudecek



PUBLICATIONS



GET INSPIRED, READ & SHARE OUR WORK





SELECTED Publications



Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.



Nat Med. 2019 Jun;25(6):920-928.PMID: 31086347





Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.



Breast Cancer Res. 2019 Dec 26;21(1):151.PMID: 31878981





A specific gene expression signature for visceral organ metastasis in breast cancer.



BMC Cancer. 2019 Apr 8;19(1):333.





Cancer-Associated Mutations in Endometriosis without Cancer.



N Engl J Med. 2017 May 11;376(19):1835-1848





Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva.



Int J Gynecol Pathol. 2017 May;36(3):289-293.





Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.



Nature. 2010 Apr 15;464(7291):1071-6.





Using Somatic Mutations to Guide Treatment Decisions: Context Matters.



JAMA Oncol. 2015 Jun;1(3):275-6.PMID: 26181166





ESR1 gene amplification in breast cancer: a common phenomenon?



Nature Genetics volume 40, pages807–808(2008)





A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.



Cancer Cell. 2007 Oct;12(4):395-402.





Our research could have never been done without the help of our patients & the following funding agencies!


Learn more >

HorlingsLab @
Antoni van leeuwenhoek Netherlands Cancer Institute



Plesmanlaan 121 1066 CX Amsterdam NL


Call us : +31-20-512-2765

HorlingsLab (c) 2019. All rights reserved. Design Hugo Horlings.